Immuno-Oncology | Specialty

The immuno-oncology condition center is a comprehensive resource for clinical news and expert insights on immuno-oncology. Read more at OncLive.

FDA Grants Priority Review to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy

January 21st 2025

The FDA granted priority review to the BLA for RP1 plus nivolumab in advanced melanoma following progression on an anti–PD-1 agent.

The OncFive: Top Oncology Articles for the Week of 1/12

January 18th 2025

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

Clinical, Molecular Factors Correlate With pCR for Durvalumab/Trastuzumab/Pertuzumab in Early HER2+ Breast Cancer

January 15th 2025

Polly Niravath, MD, discusses data from an analysis conducted in a study of durvalumab, trastuzumab, and pertuzumab in early HER2-positive breast cancer.

NGS-Based xT CDx Test Is Now Commercially Available in United States for Solid Tumor Profiling

January 15th 2025

The xT CDx assay is now available nationwide in the United States for use in solid tumor profiling.

Nivolumab Plus Gemcitabine/Cisplatin Shows Favorable OS/PFS Trend in Asian Unresectable/Metastatic Urothelial Cancer Subpopulation

January 15th 2025

First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.

Adjuvant Nivolumab Plus Chemoradiotherapy Meets DFS End Point in Locally Advanced HNSCC

January 14th 2025

Adjuvant nivolumab plus chemoradiotherapy improved disease-free survival in resected, locally advanced head and neck squamous cell carcinoma.

FDA Approval of Subcutaneous Nivolumab Represents Paradigm Shift in Solid Tumor Management

January 13th 2025

Roxana S. Dronca, MD, discusses the FDA approval of subcutaneous nivolumab across solid tumor indications.

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

January 13th 2025

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.

FDA Grants Orphan Drug Designation to Amezalpat for Advanced HCC

January 9th 2025

The FDA has granted orphan drug designation for the treatment of patients with hepatocellular carcinoma.

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC

January 9th 2025

Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC

January 8th 2025

Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma

Retifanlimab Emerges as Potential New SOC in Advanced SCAC

January 7th 2025

Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.

Dr LeVee on Immune-Related AEs Associated With ICIs in Early Breast Cancer

January 6th 2025

Alexis LeVee, MD, discusses immune-related adverse effects in patients with early breast cancer treated with immune checkpoint inhibitors.

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer

January 6th 2025

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

The OncFive: Top Oncology Articles for the Week of 12/29

January 4th 2025

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy

January 4th 2025

BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer

January 3rd 2025

Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.

OncLive’s December Roundup of Key FDA Approvals in Oncology

December 30th 2024

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC

December 30th 2024

Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

December 23rd 2024

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.